西妥昔单抗
伊立替康
医学
威罗菲尼
结直肠癌
内科学
临床终点
肿瘤科
随机化
克拉斯
随机对照试验
癌症
置信区间
转移性黑色素瘤
作者
Scott Kopetz,Shannon L McDonough,Heinz-Josef Lenz,Anthony Martin Magliocco,Chloe Evelyn Atreya,Luis A. Diaz,Carmen Joseph Allegra,Kanwal Pratap Singh Raghav,Van Karlyle Morris,Stephen E. Wang,Christopher Hanyoung Lieu,Katherine A Guthrie,Howard S. Hochster
标识
DOI:10.1200/jco.2017.35.15_suppl.3505
摘要
3505 Background: Metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 mutations have poor outcomes with standard of care chemotherapy and rarely respond to the BRAF inhibitor vemurafenib. In preclinical models, blockade of BRAF V600 by vemurafenib (V) causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab (C) with anti-tumor activity augmented by irinotecan (I). Methods: Pts with BRAF V600 mutated and extended RAS wild-type mCRC were randomized to irinotecan (180 mg/m 2 IV every 14 days) and cetuximab (500 mg/m 2 IV every 14 days) with or without vemurafenib (960 mg PO twice daily). Eligible pts had ECOG PS ≤1, and had received 1 or 2 prior regimens with no prior anti-EGFR agents. Randomization was stratified for prior irinotecan. Crossover from the control arm (IC) to the experimental arm (VIC) was allowed after documented progression. The primary endpoint was progression-free survival (PFS, investigator assessed), with 90% power to detect a HR of 0.5, with two-sided type 1 error of 5%. Results: 106 pts were enrolled (99 eligible, 49 in the experimental arm) from 12/2014 to 4/2016, with median age 62 years, 59% female, and 39% with prior irinotecan therapy. PFS was improved with the addition of vemurafenib (HR 0.42, 95% confidence interval [CI] 0.26 to 0.66, P < 0.001) with median PFS of 4.4 (95% CI 3.6 – 5.7) mos vs 2.0 (95% CI 1.8 – 2.1) months. Response rate was 16% vs 4% (P = 0.08), with disease control rate of 67% vs 22%. In pts with no prior irinotecan, median PFS was 5.7 (95% CI 3.0-6.1) months in the VIC arm vs 1.9 (95% CI 1.7 – 2.1) months in the IC arm. Grade 3/4 adverse events higher in the VIC arm included neutropenia (28% vs 7%), anemia (13% vs 0%), and nausea (15% vs 0%). There was no increase in skin toxicity or fatigue. 23 pts (46%) in the IC arm crossed over at the time of progression, with median PFS from crossover of 6.0 months (95% CI 3.7 – 7.4). Overall survival (OS) data will be mature for ASCO 2017. Conclusions: These results demonstrate the clinical benefits of the VIC triplet (vemurafenib, cetuximab, and irinotecan) in pts with treatment-refractory BRAF V600 mutated mCRC, and support VIC as a potential new treatment option in this molecular subset. Clinical trial information: NCT02164916.
科研通智能强力驱动
Strongly Powered by AbleSci AI